Recalled Medicines & supplements – Current GIS Alerts 2026
Found 700 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
3% ROZTWÓR KWASU BOROWEGO
A quality defect was found: boric acid content 0.3% instead of the required 2.8–3.2% and a non‑compliant form of the raw material, which may lead to compounding magistral medicines with incorrect strength. Potential effects: lack of treatment efficacy, possible disease complications.
CALCIUM POLFARMEX (O SMAKU TRUSKAWKOWYM)
A quality defect of the medicinal product was found in the form of an improper smell of the syrup, which may indicate irregularities in the composition or stability of the product. Potential effects: lack of efficacy, possible irritation or other adverse reactions.
ARTHRYL
The defect consists in the use of incorrect serialization data, resulting in incorrect identification of the medicinal product and failure to meet requirements for verification of authenticity and identification of the pack. Potential effects: possible use of an inappropriate or falsified drug, lack of treatment efficacy, treatment complications.
VALZEK
Presence of N-nitrosodimethylamine (NDMA) contamination above the acceptable limit was found in the active substance Valsartan, which may pose a threat to patients' health and life. Potential effects: poisoning, carcinogenic effects, health complications with long-term use.
VALZEK
This risk may be caused by the presence of N-nitrosodimethylamine (NDMA) contamination in the active substance contained in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effects and other serious health disorders with long-term exposure.
VALZEK
Potential contamination of the active substance Valsartanum with NDMA and NDEA was detected, which required suspension from the market until confirmation that levels were below acceptable limits. Potential effects: possible carcinogenic effect, complications with long‑term use.
VALZEK
Suspected exceedance of acceptable levels of NDMA and NDEA impurities in the active substance Valsartanum from the supplier Zhejiang Tianyu Pharmaceuticals; subsequent tests did not confirm limit exceedances. Potential effects: possible carcinogenic effects with long-term exposure.
OZURDEX
A silicone particle of about 300 µm in diameter was detected in some batches of the medicinal product Ozurdex, which constitutes a potential quality defect and may pose a risk to patients' health. Potential effects: complications after administration, tissue irritation, visual disturbances, serious ophthalmic complications.
REMUREL
It was found that the tested sample of the medicinal product does not meet the manufacturer's specification regarding the parameter: contamination with particles invisible to the naked eye. Potential effects: complications after injection, inflammatory reactions, lack of treatment safety.
LECALPIN
It was found that in the outer cartons intended for the medicinal product Lecalpin 20 mg there were primary packages (blisters) of the medicinal product Lecalpin 10 mg, batch No. 268018. Potential effects: lack of treatment efficacy or improper dosing.
MILVANE
Lack of information on contraindications for the use of the medicinal product Milvane in combination with certain medicines used in antiviral therapy. Potential effects: lack of efficacy, adverse reactions, treatment complications.
SPASMOLINA
Incorrect expiry date was printed on outer packaging and required safety features (unique identifier and anti-tampering device) were missing, combined with lack of batch certification and release by the Qualified Person. Potential effects: lack of treatment efficacy, use of the product after expiry date, risk of falsification or tampering, treatment complications.
KALIUM EFFERVRSCENS BEZCUKROWY
Repeated complaints were reported regarding incorrectly printed expiry dates and it was found that the products lacked a unique identifier and tamper-evident safety feature on the packaging, as well as batch certification and release by the Qualified Person. Potential effects: lack of treatment efficacy, use after expiry, falsification risk, treatment complications.
FOLACID
Incorrect expiry date was printed, the prescription products lacked a unique identifier and tamper-evident safety feature on the packaging, and batches were not certified or released by a Qualified Person. Potential effects: lack of efficacy, use after expiry date, risk of falsification, therapy complications.
SPASMOLINA
Failure to include a unique identifier and tamper-evident feature on the packaging and placing the batch on the market without recertification and release by the Qualified Person may result in distribution of a product with unverified quality and authenticity. Potential effects: lack of efficacy or complications due to use of a product with unconfirmed quality.
ANDEPIN
Lack of a unique identifier and tamper‑evident feature, together with incorrect expiry date labelling, may prevent proper medicine identification and facilitate circulation of unauthorised or expired packs. Potential effects: lack of treatment efficacy or complications related to use of expired or falsified medicine.
KALIUM EFFERVRSCENS BEZCUKROWY
Incorrect expiry date was printed on the packaging and the packs lacked a unique identifier and tamper-evident safety feature, as well as batch certification by the Qualified Person. Potential effects: lack of treatment efficacy or use of the product after expiry, possible complications.
VITAMINUM A + E SYNTEZA
The absence of a unique identifier and tamper‑evident device, together with placing batches on the market without proper certification and release by the Qualified Person, may result in incorrect identification, risk of falsification, or lack of confirmed quality and safety of therapy. Potential effects: lack of efficacy, treatment complications.
ANDEPIN
An incorrect print shortening the product expiry date by one month and reintroduction of the repackaged batch to the market without required certification and release by the Qualified Person may lead to use of the product after its actual expiry or with unverified quality. Potential effects: lack of efficacy or complications related to using the product after its expiry date.
FOLACID
Incorrect expiry date marking on the packaging and lack of batch recertification after repackaging may lead to use of the product beyond the correct expiry date or of a product improperly released to the market. Potential effects: lack of efficacy or increased adverse effects.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.